.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The LOVIT randomised trial evaluated intravenous vitamin C in adults with sepsis receiving vasopressors. Vitamin C had attracted attention because of its antioxidant and biological plausibility, but the trial tested whether that rationale translated into improved patient outcomes. The study did not show that intravenous vitamin C reduced death or persistent organ dysfunction. The result is clinically important because it provides high-quality evidence against routine use of high-dose intravenous vitamin C as a standard treatment for adults with sepsis. A later biological analysis of LOVIT explored whether different biological subtypes of sepsis might respond differently. That work is relevant to CritiCARE's precision-medicine theme, but it remains hypothesis-generating rather than a basis for routine treatment selection. For HCPs, the broader lesson is about evidence discipline. Mechanistically appealing therapies should not become routine before outcome-driven randomised evidence demonstrates benefit. At the same time, the biological heterogeneity of sepsis suggests that future targeted therapies may need better patient selection. The LOVIT programme therefore contributes to two linked conference messages: avoid ineffective routine adjuncts, and continue developing phenotype-informed approaches that can identify which patients might truly benefit from a specific therapy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The LOVIT randomised trial evaluated intravenous vitamin C in adults with sepsis receiving vasopressors. Vitamin C had attracted attention because of its antioxidant and biological plausibility, but the trial tested whether that rationale translated into improved patient outcomes. The study did not show that intravenous vitamin C reduced death or persistent organ dysfunction. The result is clinically important because it provides high-quality evidence against routine use of high-dose intravenous vitamin C as a standard treatment for adults with sepsis. A later biological analysis of LOVIT explored whether different biological subtypes of sepsis might respond differently. That work is relevant to CritiCARE's precision-medicine theme, but it remains hypothesis-generating rather than a basis for routine treatment selection. For HCPs, the broader lesson is about evidence discipline. Mechanistically appealing therapies should not become routine before outcome-driven randomised evidence demonstrates benefit. At the same time, the biological heterogeneity of sepsis suggests that future targeted therapies may need better patient selection. The LOVIT programme therefore contributes to two linked conference messages: avoid ineffective routine adjuncts, and continue developing phenotype-informed approaches that can identify which patients might truly benefit from a specific therapy.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
